Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.

Author: AbdelazizAshraf, AbdelmoniemReham, DossWahid, El-SerafyMagdy, ElakelWafaa, EsmatGamal, Gamal EldeenHadeel, KaddahMona, MedhatEman, MehrezMai, YosryAyman, ZayedNaglaa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Sofosbuvir-based regimens are effective and safe for treating recurrent HCV post-liver transplantation.
Paper Details　
Original Abstract of the Article :
Direct acting antiviral has offered treatment of hepatitis C virus (HCV) recurrence post liver transplantation (LT) with an all-oral regimen for short duration, excellent safety profile, and high sustained virological response (SVR). The aim of this study was to evaluate the efficacy and safety of s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/jmv.25362

データ提供：米国国立医学図書館（NLM）

Sofosbuvir-Based Therapy: A New Hope for Hepatitis C Recurrence After Liver Transplant

Hepatitis C virus (HCV) recurrence after liver transplant can be a significant challenge for patients, as the virus can re-infect the new liver. Direct-acting antiviral (DAA) therapy has emerged as a powerful new weapon against HCV, offering a shorter treatment duration, excellent safety profile, and high rates of sustained virological response (SVR). This study, like a team of researchers searching for a solution to a long-standing medical problem, investigates the efficacy and safety of sofosbuvir (SOF)-based regimens in treating HCV recurrence after living donor liver transplant (LDLT) in Egyptian patients.

Sofosbuvir-Based Therapy: A Promising Treatment Option

The study found that SOF-based regimens were effective in achieving SVR in patients with HCV recurrence after LDLT, demonstrating the potential of this therapy to effectively combat the virus. This discovery, like finding a hidden spring in the desert, offers a new source of hope for patients battling this challenging condition. The study also highlights the excellent safety profile of SOF-based therapy.

A Beacon of Hope for Patients

The study's findings provide valuable information for healthcare providers treating patients with HCV recurrence after LDLT. The study underscores the potential of SOF-based therapy to achieve high SVR rates while maintaining an excellent safety profile. This discovery is a beacon of hope for patients grappling with this challenging condition.

Dr.Camel's Conclusion

This study provides valuable information about the efficacy and safety of sofosbuvir-based therapy in treating HCV recurrence after living donor liver transplant. The study's findings offer a glimmer of hope for patients facing this challenging condition, demonstrating the potential of SOF-based therapy to achieve high rates of sustained virological response while maintaining an excellent safety profile.

Date :
  1. Date Completed 2020-03-17
  2. Date Revised 2020-03-17
Further Info :

Pubmed ID

30549048

DOI: Digital Object Identifier

10.1002/jmv.25362

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.